Department of Health and Human Services, through National Institutes of Health, awarded Fimbrion Therapeutics Inc of Saint Louis, MO $600,000 under the SBIR program (Phase II), with work starting 2025-09-09 and running to 2027-08-31. It is one of 3 SBIR and STTR awards Fimbrion Therapeutics Inc received in the last two years, $1,800,002 in all. Each figure links to the federal record.
The award
| Recipient | Fimbrion Therapeutics Inc (Saint Louis, MO) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $600,000 |
| Period of performance starts | 2025-09-09 |
| Period of performance ends | 2027-08-31 |
| Award number | R43AI192175 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Saint Louis, St. Louis (City) County, MO |
| Recipient registry id (UEI) | N9RQX3G4EH54 |
Want the whole picture on Fimbrion Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Fimbrion Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fimbrion Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Pyridone compounds as novel antimycobacterial drugs for tuberculosis - project summary/abstract tuberculosis (tb), caused by infection with the bacterium mycobacterium tuberculosis (mtb), is a leading cause of global mor
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-03 | Continuation | 001 | $300,000 |
| 2026-07-23 | Revision | 000 | $0 |
| 2025-09-09 | New | 000 | $300,000 |
Thiazolino-pyridone compounds as novel antimycobacterial drugs for tuberculosis - project summary/abstract tuberculosis (tb), caused by infection with the bacterium mycobacterium tuberculosis (mtb), is a leading cause of global mortality, due to infection. In 2022, ~10.6 million people were newly diagnosed with tb and 1.3 million people died from the disease. As efforts to treat tb expand, the prevalence of infections caused by drug-resistant mtb is increasing; in part due to the long duration (6 months) of combination therapy (4 antibiotics) for drug- strains (dr-tb) that are resistant to one or more frontline standard of care (soc) antibiotics, sensitive tb (ds-tb), which leads to poor compliance. Treatment for dr-tb is even longer (typically ranging from 6-24 months), with 3, 4, or more, antibiotics taken in combination. Despite the recent discovery and approval of several tb drugs, including bedaquiline (bdq), resistance is already emerging. Therefore, new classes of drugs, with new mechanisms of action (moas), that can be combined with new or existing tb drugs, are desperately needed. The success of bdq, which disrupts energy metabolism in mtb and is a component of new drug regimens for dr-tb that reduce treatment times and improve outcomes, has accompanied an explosion of drug discovery targeting respiration in mtb. In this application, fimbrion proposes to develop an ora ...
From the federal award record.
Other SBIR and STTR awards to Fimbrion Therapeutics Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-15 | Department of Health and Human Services | SBIR Phase I | $600,000 | Small molecule glycoside inhibitors of lecb for the treatment of pseudomonas infections - (record) |
| 2025-07-23 | Department of Health and Human Services | SBIR Phase I | $600,002 | Heterocyclic inhibitors of qcrb as novel drugs for infections caused by nontuberculous myc (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Fimbrion Therapeutics IncLook up Fimbrion Therapeutics Inc and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.